Research journal
Retatrutide vs Tirzepatide vs Cagrilintide
Retatrutide, tirzepatide and cagrilintide are pulled into the same metabolic-research conversation, yet they do not press the same biological buttons. The useful comparison begins with receptor targets—not with a social-media ranking of which name sounds strongest.
Start with the receptor map
Retatrutide is an investigational single molecule engineered to activate GLP-1, GIP and glucagon receptors. Tirzepatide activates GLP-1 and GIP receptors. Cagrilintide belongs to a different branch: it is a long-acting amylin analogue studied through amylin-receptor biology rather than the incretin combination used by the other two.
That makes “which is strongest?” the wrong opening question. Adding a receptor changes the mechanism as well as the possible outcome. Cagrilintide is not a one-receptor version of retatrutide, and retatrutide is not simply a higher tier of tirzepatide.
The trial contexts are not interchangeable
Tirzepatide has a large human clinical programme and approved medical uses in defined settings. Retatrutide remains investigational while phase 3 programmes develop the longer-term picture. Cagrilintide remains unapproved and is commonly studied alone or alongside a GLP-1 analogue, which is a different design from a single multi-receptor molecule.
Headline percentages are especially easy to misuse. Trials can differ in participants, duration, dose escalation, endpoints and missing-data methods. A number lifted from one paper cannot rank three compounds fairly, and none of those clinical results validates an unapproved research vial for personal use.
What community threads get right—and miss
Forums are good at surfacing practical questions about trial recruitment, plateaus, tolerability and why amylin analogues are being combined with incretin drugs. They are poor at controlled comparison. Personal posts usually involve different products, timelines and background variables, and sometimes uncertain compound identity.
For laboratory work, define the receptor question first. Use retatrutide for a triple-agonist design, tirzepatide for dual GLP-1/GIP activity, and cagrilintide for amylin-pathway research. A blend or substitution should be treated as a new experiment, not a shortcut between names.
Need concentration maths for a labelled vial mass? Use the peptide calculator.
Matching research vials
Peptomi Labs supplies research-grade materials for qualified laboratory use. These notes are not medical advice and they are not a protocol for human or veterinary use. Not for human or veterinary consumption.